Stable amyloid beta monomers and oligomers

Torleif Härd; Anders Sandberg

Stable amyloid beta monomers and oligomers

Torleif Härd (Uppfinnare)
, Anders Sandberg (Uppfinnare)

Institutionen för molekylära vetenskaper

Publikation: Patent

Sammanfattning

The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as Screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.

Originalspråk	Engelska
Patentnummer	WO/2009/128772
IPC	PCT/SE2009/050378
Prioritetsdatum	2009-10-22
Status	Publicerad - 22 okt. 2009

Bibliografisk information

Assignees:
HÄRD, Torleif [SE/SE]; SE (UsOnly)
SANDBERG, Anders [SE/SE]; SE (UsOnly)
MIVAC DEVELOPMENT AKTIEBOLAG [SE/SE]; Göteborg, SE (AllExceptUS)

Andra filer och länkar

Citera det här

@misc{e57f4dd4b9b54c7f964aaf008dd0f86c,

title = "Stable amyloid beta monomers and oligomers",

abstract = "The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as Screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides. ",

author = "Torleif H{\"a}rd and Anders Sandberg",

note = "Assignees: H{\"A}RD, Torleif [SE/SE]; SE (UsOnly) SANDBERG, Anders [SE/SE]; SE (UsOnly) MIVAC DEVELOPMENT AKTIEBOLAG [SE/SE]; G{\"o}teborg, SE (AllExceptUS); WO/2009/128772; PCT/SE2009/050378",

year = "2009",

month = oct,

day = "22",

language = "English",

type = "Patent",

}

TY - PAT

T1 - Stable amyloid beta monomers and oligomers

AU - Härd, Torleif

AU - Sandberg, Anders

N1 - Assignees: HÄRD, Torleif [SE/SE]; SE (UsOnly) SANDBERG, Anders [SE/SE]; SE (UsOnly) MIVAC DEVELOPMENT AKTIEBOLAG [SE/SE]; Göteborg, SE (AllExceptUS)

PY - 2009/10/22

Y1 - 2009/10/22

N2 - The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as Screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.

AB - The invention provides monomeric and oligomeric amyloid beta peptide isomers that are resistant towards fibrillogenesis and their use as Screening reagents or antigens in methods and pharmaceutical preparations for the treatment of Alzheimer's disease and other conditions related to protein misfolding. The alanines at positions 21 and 30, in wild type amyloid beta peptide amino acid sequence, are according to the invention replaced by cysteins, which results in an intra molecular disulphide bond. The invention further provides transgenic animals expressing modified amyloid precursor proteins or amyloid beta peptides.

UR - https://res.slu.se/id/publ/66724

UR - https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009128772

M3 - Patent

M1 - WO/2009/128772

ER -